My Application Form Status

Check the status of your application form with Angel Broking.
GIPCO moves higher after signing PPAs with GUVNL
Dec 20,2016

The announcement was made after market hours yesterday, 19 December 2016.

Meanwhile, the S&P BSE Sensex was up 36.37 points or 0.14% to 26,410.69

On the BSE, 53,000 shares were traded on the counter so far as against the average daily volumes of 49,684 shares in the past one quarter. The stock had hit a high of Rs 102.80 and a low of Rs 99.85 so far during the day. The stock had hit a 52-week high of Rs 110.05 on 11 November 2016. The stock had hit a 52-week low of Rs 74.40 on 15 March 2016. The stock had outperformed the market over the past 30 days till 19 December 2016, rising 2.93% compared with the 0.86% rise in the Sensex. The scrip had also outperformed the market in past one quarter, gaining 12.2% as against Sensexs 7.53% decline.

The small-cap power generation firm has equity capital of Rs 151.25 crore. Face value per share is Rs 10.

Gujarat Industries Power Company (GIPCO) said that the company has signed power purchase agreements (PPA) for a period of twenty five years with Gujarat Urja Vikas Nigam (GUVNL) for the entire 26 megawatts (MW) wind farm capacity of the Rojmal Wind Farm.

Gujarat Industries Power Companys net profit rose 32.66% to Rs 50.53 crore on 7.43% rise in total income to Rs 336.33 crore in Q2 September 2016 over Q2 September 2015.

Gujarat Industries Power Company is engaged in the business of electrical power generation.

Powered by Capital Market - Live News

Tata Coffee advances on plans to set up plant in Vietnam
Dec 20,2016

The announcement was made after market hours yesterday, 19 December 2016.

Meanwhile, the S&P BSE Sensex was up 20.70 points or 0.08% at 26,395.40.

On the BSE, 16,000 shares were traded on the counter so far as against the average daily volumes of 1.41 lakh shares in the past one quarter. The stock had hit a high of Rs 116.15 and a low of Rs 114.50 so far during the day.

The stock had a hit 52-week high of Rs 150.05 on 20 October 2016 and a 52-week low of Rs 81.70 on 17 February 2016. The stock had underperformed the market over the past one month till 19 December 2016, advancing 0.44% compared with the Sensexs 0.86% rise. The scrip had also underperformed the market over the past one quarter declining 8.38% as against the Sensexs 7.89% fall.

The small-cap company has equity capital of Rs 18.68 crore. Face value per share is Rs 1.

The latest decision from Tata Coffee to set up a plant in Vietnam will further strengthen the companys growth in the premium instant coffee segment. Instant coffee accounts for about 20% of the global coffee consumption with freeze dried instant coffee being the most premium.

The plant in Vietnam will serve Tata Coffees global customers with new product mixes of freeze dried coffee.

Tata Coffees Managing Director Sanjiv Sarin said that Vietnam offers an attractive business environment besides being the largest Robusta Coffee growing region. He further added that the plant will help the company to further expand its global footprint.

Tata coffees consolidated net profit rose 61.9% to Rs 44.65 crore on 8.5% decline in net sales to Rs 355.55 crore in Q2 September 2016 over Q2 September 2015.

Tata coffee is leading player in coffee business.

Powered by Capital Market - Live News

Wockhardt gains as Chikalthana plant gets GMP certificate from UK MHRA
Dec 20,2016

The announcement was made after market hours yesterday, 19 December 2016.

Meanwhile, the BSE Sensex was up 22.59 points, or 0.09%, to 26,397.29.

On the BSE, so far 86,000 shares were traded in the counter, compared with average daily volumes of 2.48 lakh shares in the past one quarter. The stock had hit a high of Rs 704 and a low of Rs 692.25 so far during the day.

The stock hit a 52-week high of Rs 1,647 on 13 January 2016. The stock hit a 52-week low of Rs 659 on 23 November 2016. The stock had underperformed the market over the past 30 days till 19 December 2016, falling 6.76% compared with the 0.86% rise in the Sensex. The scrip had also underperformed the market in past one quarter, falling 25.25% as against Sensexs 7.53% decline.

The mid-cap company has equity capital of Rs 55.27 crore. Face value per share is Rs 5.

Wockhardt said that UK Medicines and Healthcare products Regulatory Agency (MHRA) has confirmed that general compliance with the principles and guidelines of Good Manufacturing Practice of the companys manufacturing unit at L-1, Chikalthana, Aurangabad. In view of this, the approval status of the said unit continues. Further, UK MHRA has considered the said manufacturing unit suitable for Risk based Inspection with reduced inspection frequency of 2 years from the existing inspection frequency of 1 year.

On a consolidated basis, net profit of Wockhardt declined 81.59% to Rs 17.02 crore on 13.41% decline in net sales to Rs 1064.69 crore in Q2 September 2016 over Q2 September 2015.

Wockhardt is a research based and technology intensive global pharmaceutical and biotechnology company.

Powered by Capital Market - Live News

New order win boosts HPL Electric & Power
Dec 20,2016

The announcement was made during market hours today, 20 December 2016.

Meanwhile, the S&P BSE Sensex was up 19.25 points or 0.07% at 26,393.95

On the BSE, 64,000 shares were traded on the counter so far as against the average daily volumes of 1.02 lakh shares in the past two weeks. The stock had hit a high of Rs 106.80 and a low of Rs 101.85 so far during the day. The stock had hit a record high of Rs 198 on 4 October 2016. The stock had hit a record low of Rs 74.20 on 23 November 2016. The stock had underperformed the market over the past 30 days till 19 December 2016, falling 0.2% compared with the 0.86% rise in the Sensex.

The small-cap company has equity capital of Rs 64.30 crore. Face value per share is Rs 10.

Speaking on the occasion of receiving the formal order, Gautam Seth, Joint Managing Director, of HPL Electric & Power said that the company has fully dedicated teams working on the advancement of street lighting system that help in energy efficiency. For Bhopal Smart City lighting order, HPL Electric & Power has earlier entered as part of a consortium with Bharti lnfratel and Ericsson, the company said.

Shares of HPL Electric & Power had debuted on the bourses on 4 October 2016. The stock had debuted at Rs 190.05, a discount of 5.92% to the initial public offer (IPO) price of Rs 202. The IPO of HPL Electric and Power had ended on 26 September 2016. The IPO received bids for 11.64 crore shares and it was subscribed 8.06 times. The price band for the IPO was fixed at Rs 175 to Rs 202 per share.

On a consolidated basis, HPL Electric and Powers net profit dropped 73.71% to Rs 3.97 crore 35.04% fall in net sales to Rs 213.95 crore in Q2 September 2016 over Q2 September 2015.

HPL Electric & Power manufactures electrical appliances, switch-gears, electronic energy meters and electrical protection equipment.

Powered by Capital Market - Live News

Opto Circuits gallops after new order win
Dec 20,2016

The announcement was made after market hours yesterday, 19 December 2016.

Meanwhile, the S&P BSE Sensex was up 41.47 points or 0.16% at 26,416.17

On the BSE, 5.79 lakh shares were traded on the counter so far as against the average daily volumes of 2.33 lakh shares in the past one quarter. The stock had hit a high of Rs 11.14 and a low of Rs 10.50 so far during the day. The stock had hit a 52-week high of Rs 16.84 on 6 January 2016. The stock had hit a 52-week low of Rs 8.12 on 12 February 2016. The stock had underperformed the market over the past 30 days till 19 December 2016, falling 0.75% compared with the 0.86% rise in the Sensex. The scrip had also underperformed the market in past one quarter, sliding 26.15% as against Sensexs 7.53% decline.

The small-cap company has equity capital of Rs 242.32 crore. Face value per share is Rs 10.

Vinod Ramnani, Chairman & Managing Director of Opto Circuits (India) commented that the latest long term contract helps the company in strengthening its relationship with Philips Health Care.

On consolidated basis, Opto Circuits (India) reported net loss of Rs 258.72 crore in Q2 September 2016 as against net profit of Rs 62.14 crore in Q2 September 2015. Net sales declined 40.24% to Rs 46.67 crore in Q2 September 2016 over Q2 September 2015.

Opto Circuits (India) is a leading manufacturer of healthcare equipment in India.

Powered by Capital Market - Live News

Cipla gains on fund raising plan
Dec 20,2016

The announcement was made after market hours yesterday, 19 December 2016.

Meanwhile, the BSE Sensex was up 51.33 points, or 0.19%, to 26,426.03.

On the BSE, so far 6,433 shares were traded in the counter, compared with average daily volumes of 1.38 lakh shares in the past one quarter. The stock had hit a high of Rs 574.50 and a low of Rs 570.50 so far during the day.

The stock hit a 52-week high of Rs 660 on 29 December 2015. The stock hit a 52-week low of Rs 458.25 on 25 May 2016. The stock had outperformed the market over the past 30 days till 19 December 2016, rising 3.40% compared with the 0.86% rise in the Sensex. The scrip had also outperformed the market in past one quarter, falling 5.56% as against Sensexs 7.53% decline.

The large-cap drug maker has equity capital of Rs 160.88 crore. Face value per share is Rs 2.

Cipla said its board has approved raising funds up to Rs 2000 crore. It could be via issue of shares or American Depository Receipts (ADRs) or Global Depository Receipts (GDRs) or Foreign Currency Convertible Bonds (FCCBs) or other securities, whether denominated in rupee or foreign currency through a public issue or a private placement, it said.

The board also approved raising of funds up to Rs 2000 crore by issue of non convertible debentures (NCDs) or bonds, in rupee or foreign currency through a public issue or a private placement, it added. The fund raising is subject to necessary permissions sanctions and approvals and the company is seeking approval of shareholders for the aforesaid enabling resolutions by means of postal ballot, Cipla said.

On a consolidated basis, Ciplas net profit dropped 34.75% to Rs 354.34 crore on 8.66% rise in net sales to Rs 3671.88 crore in Q2 September 2016 over Q2 September 2015.

Cipla is a global pharmaceutical company.

Powered by Capital Market - Live News

Engineers India advances after setting record date for bonus issue
Dec 19,2016

The announcement was made during market hours today, 19 December 2016.

Meanwhile, the S&P BSE Sensex was down 81.36 points or 0.31% at 26,408.20

On the BSE, 2.34 lakh shares were traded on the counter so far as against the average daily volumes of 2 lakh shares in the past one quarter. The stock hit a high of Rs 317.80 in intraday trade so far, which is 52-week high for the counter. The stock hit a low of Rs 307.30 so far during the day. The stock had hit a 52-week low of Rs 143.25 on 17 February 2016. The stock had outperformed the market over the past 30 days till 16 December 2016, rising 14.61% compared with the 1% rise in the Sensex. The scrip also outperformed the market in past one quarter, gaining 19.22% as against Sensexs 7.38% decline.

The large-cap company has equity capital of Rs 168.47 crore. Face value per share is Rs 5.

Engineers India had on 16 November 2016 said that its board has approved 1:1 bonus issue of shares.

Engineers Indias net profit rose 21.42% to Rs 93.75 crore on 22.6% decline in total income to Rs 394.99 crore in Q2 September 2016 over Q2 September 2015.

State-run Engineers India provides engineering consultancy and EPC services, mainly to the oil and gas and petrochemical industries. The company has also diversified into sectors like infrastructure, water and waste management, solar and nuclear power and fertilizers to leverage its strong technical competencies and track record. The government of India holds 59.37% in Engineers India (as per shareholding pattern as on 30 September 2016).

Powered by Capital Market - Live News

Anuh Pharma corrects on profit booking
Dec 19,2016

Meanwhile, the BSE Sensex was down 107.22 points, or 0.40%, to 26,382.34.

On the BSE, so far 31,000 shares were traded in the counter, compared with average daily volumes of 17,114 shares in the past one quarter. The stock had hit a high of Rs 244.45 and a low of Rs 221.75 so far during the day.

The stock hit a 52-week high of Rs 344 on 21 December 2015. The stock hit a 52-week low of Rs 159 on 21 April 2016. The stock had outperformed the market over the past 30 days till 16 December 2016, rising 17.77% compared with the 1% rise in the Sensex. The scrip had also outperformed the market in past one quarter, rising 3.40% as against Sensexs 7.38% decline.

The small-cap company has equity capital of Rs 12.53 crore. Face value per share is Rs 5.

Shares of Anuh Pharma surged 16.54% to settle at Rs 238.55 on Friday, 16 December 2016, after the company announced that French National Agency for Medicines and Health Products Safety (ANSM) considers manufacturing site of the company at MIDC Tarapur in Maharashtra in compliance with principles of good manufacturing practices (GMP) for active substances and has granted European Union good manufacturing practices (EUGMP) certificate for Erythromycin Ethyl Succinate and Pyrazinamide products. ANSM carried out the inspection of the manufacturing site on 16 September 2016.

Separately, Anuh Pharma announced that World Health Organisation (WHO), Geneva, considers the manufacturing site of the company at MIDC Tarapur in Maharashtra in compliance to WHO GMPs for Pyrazinamide APIMF158 and Sulfadoxine APIMF234, active pharmaceutical ingredients. The inspection of the manufacturing site by the WHO was carried out on 16 September 2016.

Both the announcements were made during market hours on Friday, 16 December 2016.

Anuh Pharmas net profit dropped 34.5% to Rs 4.87 crore on 44.2% drop in net sales to Rs 50.07 crore in Q2 September 2016 over Q2 September 2015.

Anuh Pharma manufactures active pharmaceutical ingredients (APIs).

Powered by Capital Market - Live News

GSFC, FACT spurt after caprolactam prices hit 2-year high
Dec 19,2016

Gujarat State Fertilizers & Chemicals (GSFC) (up 9.29% to Rs 95.85) and Fertilizers and Chemicals Travancore (FACT) (up 5.42% to Rs 24.30), edged higher.

The S&P BSE Sensex was down 50.03 points, or 0.19% at 26,439.53.

According to media reports, Asian caprolactam hit a 2-year high on Thursday, 15 December 2016, with the CFR Far East Asia marker assessed by S&P Global Platts at $1,830 per metric tonne. The last time the price was at this level was on 18 December 2014, when the Platts CFR Far East Asia marker was assessed at $1,900 a metric tonne.

Caprolactam, a derivative of benzene, is used for manufacturing nylon, tyre-cord, textile filament yarn and engineering plastics.

GSFC and FACT are two major manufacturers of caprolactam in India. GSFC has two caprolactam plants having rated capacities of 20,000 tonnes per annum (TPA) and 50,000 TPA. Meanwhile, FACT has the capacity to produce 50,000 tonnes of caprolactam in a year. FACT exports caprolactam to various countries, including the US.

Powered by Capital Market - Live News

MSR India gains after winning order
Dec 19,2016

The announcement was made during trading hours today, 19 December 2016.

Meanwhile, the BSE Sensex was down 58.42 points, or 0.22%, to 26,431.14.

On the BSE, so far 2,398 shares were traded in the counter, compared with average daily volumes of 21,214 shares in the past one quarter. The stock had hit a high of Rs 52.15 and a low of Rs 51 so far during the day.

The stock hit a 52-week high of Rs 150 on 20 April 2016. The stock hit a 52-week low of Rs 35.10 on 30 November 2016. The stock had underperformed the market over the past 30 days till 16 December 2016, sliding 15.87% compared with the 1% rise in the Sensex. The scrip had also underperformed the market in past one quarter, falling 24.14% as against Sensexs 7.38% decline.

The small-cap company has equity capital of Rs 31.44 crore. Face value per share is Rs 5.

MSR India said it secured prestigious Vikram Sarabhai Space Centre (ISRO) order for manufacturing special purpose components. The company bagged this contract for second time after completing its first order in a record time.

After entering into aerospace & defense sector, this is a biggest achievement for the company to bag consecutive order from ISRO. The company said it expects to generate huge revenue from these work orders.

Net profit of MSR India rose 137.5% to Rs 0.19 on 9.7% rise in net sales to Rs 41.69 crore in Q2 September 2016 over Q2 September 2015.

MSR Indias product portfolio consists of copper bottles, ready-to-eat energy powder, FMCG products, extrusion and forging products. The company makes special purpose components for aerospace & defense industry.

Powered by Capital Market - Live News

New orders boost NBCC (India)
Dec 19,2016

The announcement was made during market hours today, 19 December 2016.

Meanwhile, the BSE Sensex was down 65.63 points, or 0.25%, to 26,423.93

On the BSE, 55,000 shares were traded on the counter so far as against the average daily volumes of 2.08 lakh shares in the past one quarter. The stock had hit a high of Rs 227.30 and a low of Rs 223.50 so far during the day. The stock hit a record high of Rs 299.20 on 5 October 2016. The stock hit a 52-week low of Rs 162 on 12 February 2016. The stock had outperformed the market over the past 30 days till 16 December 2016, rising 3.53% compared with the 1% rise in the Sensex. The scrip, however, underperformed the market in past one quarter, declining 9.51% as against Sensexs 7.38% decline.

The large-cap company has equity capital of Rs 120 crore. Face value per share is Rs 2.

NBCC (India) said it has secured new works for the construction of residential cum training complex for Special Protection Group (SPG) at Sector - 21, Dwarka, New Delhi and construction of guest house for government of Gujarat at Akbar Road, New Delhi amounting to Rs 466.41 crore and Rs 130 crore, respectively, in December 2016.

NBCC (India)s consolidated net profit rose 1.42% to Rs 69.11 crore on 15.75% increase in net sales to Rs 1224.41 crore in Q2 September 2016 over Q2 September 2015.

NBCC (India) is a blue-chip Government of India (GoI) Navratna Enterprise under the Ministry of Urban Development, in construction sector. The GoI held 90% stake in the firm (as per shareholding pattern as on 30 September 2016).

Powered by Capital Market - Live News

Manappuram Finance leads losers on BSEs A group
Dec 19,2016

Manappuram Finance slipped 4.77% at Rs 63.95. The stock topped the losers in A group. On the BSE, 5.98 lakhshares were traded on the counter so far as against the average daily volumes of 4.42 lakh shares in the past two weeks.

Oberoi Realty declined 3.67% at Rs 316.60. The stock was the second biggest loser in A group. On the BSE, 1.78 lakh shares were traded on the counter so far as against the average daily volumes of 22,000 shares in the past two weeks.

EID Parry India fell 3.47% at Rs 257.45. The stock was the third biggest loser in A group. On the BSE, 13,000 shares were traded on the counter so far as against the average daily volumes of 28,000 shares in the past two weeks.

Amtek Auto corrected 3.22% at Rs 34.60. The stock was the fourth biggest loser in A group. On the BSE, 1.65 lakh shares were traded on the counter so far as against the average daily volumes of 3.19 lakh shares in the past two weeks.

Hindustan Zinc skid 3.22% at Rs 271.60. The stock was the fifth biggest loser in A group. On the BSE, 64,000 shares were traded on the counter so far as against the average daily volumes of 1.05 lakh shares in the past two weeks.

Powered by Capital Market - Live News

Volumes jump at Techno Electric & Engineering Company counter
Dec 19,2016

Techno Electric & Engineering Company clocked volume of 3.03 lakh shares by 13:29 IST on BSE, a 21.91-times surge over two-week average daily volume of 14,000 shares. The stock fell 1.12% to Rs 296.90.

TV18 Broadcast notched up volume of 52.01 lakh shares, a 18.26-fold surge over two-week average daily volume of 2.85 lakh shares. The stock shed 0.92% to Rs 37.70.

Repco Home Finance saw volume of 3.16 lakh shares, a 9.98-fold surge over two-week average daily volume of 32,000 shares. The stock rose 0.88% to Rs 530.25. A bulk deal of 3.03 lakh shares was executed on the scrip at Rs 528 per share at 10:56 IST on BSE.

Oberoi Realty clocked volume of 1.78 lakh shares, a 8.10-fold surge over two-week average daily volume of 22,000 shares. The stock lost 3.67% to Rs 316.60.

Gujarat State Fertilizers & Chemicals saw volume of 8.10 lakh shares, a 7.26-fold rise over two-week average daily volume of 1.12 lakh shares. The stock jumped 8.21% to Rs 94.90.

Powered by Capital Market - Live News

JK Lakshmi Cement gains on boards nod to raise funds
Dec 19,2016

The announcement was made on Saturday, 17 December 2016.

Meanwhile, the S&P BSE Sensex was down 61.51 points or 0.23% at 26,428.05.

On the BSE, 2,535 shares were traded on the counter so far as against the average daily volumes of 24,104 shares in the past one quarter. The stock had hit a high of Rs 349 and a low of Rs 343.30 so far during the day.

The stock had hit a record high of Rs 513.75 on 6 October 2016 and a 52-week low of Rs 253 on 12 February 2016. The stock had underperformed the market over the past one month till 16 December 2016, declining 10.37% compared with the Sensexs 0.73% rise. The scrip had also underperformed the market over the past one quarter declining 27.42% as against the Sensexs 7.38% fall.

The mid-cap company has equity capital of Rs 58.84 crore. Face value per share is Rs 5.

The directors of the company appointed a debenture trustee and a share transfer agent for the proposed issue of non-convertible debentures (NCDs) of upto Rs 300 crore on private placement basis.

JK Lakshmi Cement reported net profit of Rs 24.91 crore in Q2 September 2016, as against net loss of Rs 8.38 crore in Q2 September 2015. Net sales rose 1.5% to Rs 655.57 crore in Q2 September 2016 over Q2 September 2015.

JK Lakshmi Cement is a cement manufacturer. It caters to infrastructure and construction sectors.

Powered by Capital Market - Live News

Lupin rises after launching Voriconazole tablets in US
Dec 19,2016

The announcement was made during market hours today, 19 December 2016.

Meanwhile, the S&P BSE Sensex was down 66.58 points or 0.25% at 26,422.98

On the BSE, 23,000 shares were traded on the counter so far as against the average daily volumes of 94,617 shares in the past one quarter. The stock had hit a high of Rs 1,493.80 and a low of Rs 1,460 so far during the day. The stock had hit a 52-week high of Rs 1,911.55 on 9 February 2016. The stock had hit a 52-week low of Rs 1,294.05 on 29 March 2016. The stock had outperformed the market over the past 30 days till 16 December 2016, rising 3.93% compared with the 1% rise in the Sensex. The scrip also outperformed the market in past one quarter, declining 4.52% as against Sensexs 7.38% decline.

The large-cap company has equity capital of Rs 90.28 crore. Face value per share is Rs 2.

Lupin announced today, 19 December 2016 that it has launched its Voriconazole Tablets, 50 mg and 200 mg and Voriconazole Oral Suspension, 40 mg/ml having received an approval from the United States Food and Drug Administration (USFDA) earlier to market a generic equivalent of PF Prism C.Vs Vfend Tablets, 50 mg and 200 mg and Vfend Oral Suspension, 40 mg/ml.

Voriconazole Tablets, 50 mg and 200 mg and Voriconazole Oral Suspension, 40 mg/ml are the AB rated generic equivalent of PF Prism C.Vs Vfend Tablets, 50 mg and 200 mg and Vfend Oral Suspension, 40 mg/ml. It is indicated for use in patients 12 years of age and older in the treatment of various fungal infections. Vfend Tablets, 50 mg & 200 mg had annual US sales of $81 million as per the IMS MAT September 2016 data while Vfend Oral Suspension, 40 mg/ml had annual US sales of $15.2 million as per the IMS MAT September 2016 data.

Lupins consolidated net profit jumped 57.76% to Rs 662.19 crore on 31.9% rise in net sales to Rs 4211.18 crore in Q2 September 2016 over Q2 September 2015.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally. The company is a significant player in the cardiovascular, diabetology, asthma, pediatric, central nervous system (CNS), GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Powered by Capital Market - Live News